Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

High-Dose Deferoxamine in Intracerebral Hemorrhage (HI-DEF)

This study has suspended participant recruitment.
(Recruitment halted by DSMB due to increased incidence of ARDS). Modifications to minimize dug toxicity with this high dose and the risk of ARDS are underway)
Sponsor:
Collaborators:
Medical University of South Carolina
Massachusetts General Hospital
Tufts Medical Center
University of Massachusetts, Worcester
University of Pennsylvania
Johns Hopkins University
University of Maryland
University of Virginia
Duke University
University of North Carolina
University of Florida
The Cleveland Clinic
Henry Ford Hospital
Ohio State University
St. Joseph's Hospital and Medical Center, Phoenix
University of California, San Francisco
Oregon Health and Science University
Yale New Haven Health System Center for Healthcare Solutions
University of Iowa
Hartford Hospital
The University of Texas Health Science Center, Houston
Rhode Island Hospital
Stanford University
University of Washington
University of Calgary, Foothills Hospital
CHU de Québec - Hôpital de l'Enfant-Jésus
University of Alberta
Dalhousie University
Information provided by (Responsible Party):
Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT01662895
First received: July 30, 2012
Last updated: February 25, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
No publications provided by Beth Israel Deaconess Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):